On Monday, September 21st, China's A-share market kicked off the new trading week with a positive opening. Concepts such as MLCC and Yttrium Oxide led the early session surge, followed by a strong push from the pharmaceutical and biotech sectors roughly thirty minutes after the bell, ultimately establishing them as the day's dominant market leaders.

The broad-based uptrend extended Friday's gains, with all major indices opening higher and climbing throughout the session. Over 4,500 stocks closed in positive territory, reflecting healthy overall profitability across the market.

Why did the key indices continue their coordinated advance today? In the previous session, US stocks closed mixed, though most large-cap tech and semiconductor names posted gains. In the Asia-Pacific region, South Korea's market advanced, with Samsung Electronics rising over 4% and SK Hynix edging up. Japan's market remained closed for a three-day holiday, removing one variable. For the A-share market, this meant no external selling pressure to drag sentiment, allowing domestic factors to take the lead.

Despite global liquidity tightening, the A-share market moved higher against the trend. The Federal Reserve's September meeting delivered its first rate hike in three years, raising rates by 25 basis points to 3.75%-4%, with rising energy prices cited as a key driver of inflation. Higher overseas funding costs theoretically pressure emerging markets. However, this hike was a well-anticipated event already priced in by markets. The simultaneous strength in both A-shares and Hong Kong stocks suggests this rally is not driven by broad liquidity expansion but rather by domestic industrial logic and structural opportunities taking center stage.

Meanwhile, policy support intensified recently. On September 18th, the Ministry of Industry and Information Technology and nine other departments jointly issued the "15th Five-Year Plan for Pharmaceutical Industry Development." On September 20th, the National Medical Products Administration expressed support for expanding opening-up and international cooperation in the pharmaceutical sector during a State Council Information Office briefing. These two significant announcements combined to channel early capital flows into the pharmaceutical sector on Monday.

Regarding the current market outlook, GF Securities believes a new wave of "perfectly timed rally opportunities" has arrived, recommending a focus on high-performing AI supply chains from Q3 earnings reports, alongside niche alpha opportunities in non-AI sectors such as pharmaceuticals, shipping, shipbuilding, and select export chain segments. Founder Securities argues that "the rebound window is open, and the return of tech will continue." China Galaxy Securities adopts a more cautious stance, warning that cross-holiday risk premiums combined with quarter-end institutional assessment constraints could lead to continued market volatility and sector rotation.

Today, the pharmaceutical sector took over the baton from the AI supply chain, leading gains across all sub-sectors. CRO, anti-cancer drugs, innovative drugs, stem cells, in-vitro diagnostics, gene sequencing, and peptide drugs dominated the top of the concept gainers list. Individual stocks such as Novoprotein (688137), Novogene Co Ltd (688315), and Tellgen Corporation (300642) all hit the 20% daily limit. Meanwhile, Baihua Pharmaceutical (600645), Watson Pharma (300110), Harbin Gloria Pharmaceuticals (002900), Hainan Haiyao Co Ltd (000566), and Xinhua Pharmaceutical (000756) all reached their 10% daily limits.

Two policies, one domestic and one international, served as direct catalysts for the pharmaceutical sector's comprehensive rally. The domestic catalyst, the "15th Five-Year Plan for Pharmaceutical Industry Development," sets highly specific targets: by 2030, biopharmaceutical R&D and application will rank among the world's leading positions; the biopharmaceutical industry will accelerate its emergence as a new national pillar industry; innovative drug industry scale will grow at an average annual rate exceeding 20%; more than five products will achieve global annual sales exceeding $1 billion; average R&D investment intensity among listed pharmaceutical companies will reach over 10% annually; and first-in-class drugs will account for 25% or more of the global total. The plan also emphasizes accelerating the application of AI, quantum computing, supercomputing, and computational medicine to drug discovery. This target-setting approach matters because it is not just a vague expression of support but provides quantifiable, verifiable benchmarks that can be tracked and evaluated over the next five years.

The external catalyst came on September 20th when the National Medical Products Administration stated its support for the pharmaceutical industry's scaled, intensive, and high-end development, encouraging foreign companies to bring original drugs and high-end medical equipment to domestic production while also encouraging Chinese companies to expand globally. This statement provides direct reassurance for innovative drug companies seeking overseas expansion. Industry insiders note that unlike previous "expectation-driven" rallies, the money in the pharmaceutical sector is now actually arriving. The 2025-2026 period represents a peak for BD contract signings, with the 2026 interim reports serving as a critical settlement milestone as upfront payments, milestone payments, and sales royalties from previously signed licensing deals begin appearing in financial statements. Statistics show that the potential total value of out-licensing deals for Chinese innovative drugs this year has exceeded $120 billion, up approximately 36% year-on-year. In Q1 2026 alone, total transaction value reached $61.4 billion, representing a significant global share of pharmaceutical BD activity. This suggests that "BD stories" are increasingly becoming "operating revenues."

Industry observers believe the biopharmaceutical sector's fundamental prosperity remains unchanged, with the driving force shifting from "valuation expansion" to "earnings and globalization realization." Once this transition completes, the sustainability of the rally typically surpasses that of pure thematic speculation. The policy's five-year quantitative targets essentially lay out a long runway, and global capital is reallocating toward biotech assets, while domestic innovative drug valuations remain at historical lows. Industrial Securities (601377) recommends focusing on innovative drug companies with differentiated R&D capabilities, global best-in-class potential, and products entering their volume growth phase. Shenwan Hongyuan Group (000166) suggests that with Q3 earnings season approaching, leading companies with strong earnings visibility are likely to continue attracting capital inflows. Based on 2026 interim financial data, numerous pharmaceutical stocks have delivered impressive earnings growth.

Beyond pharmaceuticals, tech stocks also maintained their upward trajectory today, with MLCC concepts leading gains early in the session. Notably, Sinocera Advanced Materials (300285) hit its daily limit for the fifth consecutive session, while Shuangxing New Material (002585) also hit the limit once again. Although the MLCC sector moderated its pace today, industry insiders believe its fundamental logic remains robust. On September 10th, global MLCC leader Murata Manufacturing issued a product line optimization notice, announcing production stops for certain consumer-grade conventional and automotive-spec MLCC part numbers, reallocating capacity from low-margin products toward high-value-added AI server components. Taiyo Yuden has been adjusting prices on certain products since September, stating in correspondence that "the company currently cannot fully meet demand or deliver according to schedules, and even with this price adjustment, on-time delivery cannot be guaranteed." Samsung Electro-Mechanics implemented a uniform 30% increase in MLCC shipment prices effective August 1st and signed a long-term supply contract for AI server MLCCs valued at approximately 1.07 trillion Korean won in early September, with order visibility extending to the end of 2027. TrendForce data indicates Samsung Electro-Mechanics has taken the lead in raising Q4 2026 pricing, with consumer-grade X5R products expected to rise an average of 25%-30% and AI server high-end X6S products expected to rise 10%-20%, while other manufacturers' Q4 quotes are projected to increase 10%-20%. On the order front, as of late June, the book-to-bill ratios for Murata, Samsung Electro-Mechanics, and Taiyo Yuden stood at 1.30, 1.31, and 1.25 respectively, with monthly June MLCC shipments reaching 140 billion, 98 billion, and 40 billion units respectively, all setting five-year monthly records. The mutual confirmation of pricing, orders, and shipment data indicates this is not merely thematic speculation but a structural cyclical trend driven by AI demand. Goldman Sachs analysts note that MLCC has risen to become the third-largest cost component in current AI server bill-of-materials, trailing only GPUs and memory chips. Industry estimates suggest a single AI server requires eight to twelve times more MLCCs than a traditional server, fundamentally challenging the market's previous perception of MLCCs as low-value consumables. However, after the recent sustained rally, short-term capital requires profit-taking opportunities. For the MLCC sector, companies with solid earnings, production capacity, and technical barriers are likely to receive priority attention, while purely conceptual plays with poor fundamentals may be discarded by the market.